Relmapirazin

Summary

Relmapirazin (CHEMBL1949708) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including chronic kidney disease and acute kidney injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 9
• Chemistry: 372.29 Da · C12H16N6O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1949708
Name	Relmapirazin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	53389120
Molecular formula	C12H16N6O8
Molecular weight	372.29
InChIKey	XHNJXRDGTITISI-QWWZWVQMSA-N

SMILES: C([C@H](C(=O)O)NC(=O)C1=C(N=C(C(=N1)N)C(=O)N[C@H](CO)C(=O)O)N)O

IUPAC name: (2R)-2-[[3,6-diamino-5-[[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl]pyrazine-2-carbonyl]amino]-3-hydroxypropanoic acid

Also known as: Lumitrace, Mb-102, MB-102, Relmapirazin, Relmapirazina, Relmapirazine, RELMAPIRAZIN

Patent coverage: 124 distinct patent families (391 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0003884
acute kidney injury	2	MONDO:0002492	HP:0001919
CD4+/CD56+ hematodermic neoplasm	1	MONDO:0019467	EFO:0010580

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE3	3
EARLY_PHASE1	2
Not specified	2
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05425719	PHASE3	COMPLETED	Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
NCT05777174	PHASE3	COMPLETED	Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
NCT05943977	PHASE3	COMPLETED	A Bioequivalence and Efficacy Study of MB-102 (Relmapirazin) in Chinese Participants
NCT04109482	PHASE1/PHASE2	TERMINATED	Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
NCT07080008	PHASE1	RECRUITING	Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
NCT04008121	EARLY_PHASE1	RECRUITING	Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
NCT03962998	EARLY_PHASE1	COMPLETED	Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
NCT07335614	Not specified	NOT_YET_RECRUITING	Evaluation of Protein Loading on Measurement of Renal Reserve
NCT07349797	Not specified	NOT_YET_RECRUITING	MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).